IWM
HUMA icon

Inlight Wealth Management’s Humacyte HUMA Stock Holding History

Inlight Wealth Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,700
Closed -$4.6K – 264
2025
Q1 		$4.6K Buy
+2,700
New +$10.1K ﹤0.01% 205

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Inlight Wealth Management's HUMA Position: Q2 2025 in Review

Inlight Wealth Management sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 2,700 shares — an estimated $4.6K sold.

Inlight Wealth Management first reported a position in HUMA in Q1 2025 and held it in 1 quarter. The position peaked at $4.6K in Q1 2025. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • Inlight Wealth Management reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • Inlight Wealth Management sold 2,700 Humacyte shares in Q2 2025, an estimated $4.6K.
  • Inlight Wealth Management first reported a position in Humacyte in Q1 2025 and held it in 1 quarter.
  • Inlight Wealth Management's Humacyte position peaked at $4.6K in Q1 2025.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Inlight Wealth Management's 13F filing for Q2 2025, filed 22 Jul 2025.